The CD38+HLA-DR+ T cells with activation and exhaustion characteristics as predictors of severity and mortality in COVID-19 patients
Authors:
Open Access
- 30 April 2025
- journal article
- immunology
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1577803
Abstract
Background: The COVID-19 pandemic remains a global health challenge. Severe cases often respond poorly to standard treatments, highlighting the necessity for novel therapeutic targets and early predictive biomarkers.Methods: We utilized flow cytometry to analyze peripheral immune cells from healthy, bacterial pneumonia patients, and COVID-19 patients. The expansion of activated T cells (CD38+HLA-DR+), monocytes, and myeloid-derived suppressor cells (MDSCs) were detected and correlated with clinical outcomes to evaluate prognostic potential. The single-cell RNA sequencing (scRNA-seq) was applied to characterize the critical cell subset associated with prognosis and elucidate its phenotype in COVID-19.Results: We revealed a significant increase in CD38+HLA-DR+ T cells in non-survivor COVID-19 patients, establishing them as an independent risk factor for 28-day mortality. The scRNA-seq analysis identified the CD38+HLA-DR+ T cell as a terminally differentiated, Treg-like subset exhibiting both activation and exhaustion characteristics. This subset presented the highest IL-6 and IL-10 mRNA levels among all T-cell subsets. Further functional analysis demonstrated its enhanced major histocompatibility complex class II (MHC-II) cross-signaling and correspondingly enriched cytoskeletal rearrangement processes. In addition, there was dysregulated NAD+ metabolism in CD38+HLA-DR+ T cells via scRNA-seq, accompanied by elevated adenosine and decreased NAD+ levels in serums from COVID-19 patients.Conclusions: We identified the selective expansion of CD38+HLA-DR+ T cells as a novel prognostic indicator for COVID-19 outcomes. These cells’ unique activated-exhausted phenotype, along with their impact on NAD+ metabolism, provides new insights into COVID-19 immunopathogenesis.Keywords
This publication has 51 references indexed in Scilit:
- Diagnosis and treatment protocol for COVID‐19 patients (Tentative 10th Version)Health Care Science, 2023
- A universal MHCII technology platform to characterize antigen-specific CD4+ T cellsCell Reports Methods, 2023
- Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19Advanced Science, 2021
- Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19Cell, 2020
- Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell CompartmentCell, 2020
- Management of COVID-19 Respiratory DistressJAMA, 2020
- NAD metabolism: Implications in aging and longevityAgeing Research Reviews, 2018
- Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus PatientsArthritis & Rheumatology, 2017
- HIV Infection Decreases Intracellular Nicotinamide Adenine Dinucleotide [NAD]Biochemical and Biophysical Research Communications, 1995
- MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activationCell, 1994